

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**VOLUNTARY ANNOUNCEMENT –
AURORA A INHIBITOR JS112 RECEIVED THE ACCEPTANCE NOTICE
FOR THE INVESTIGATIONAL NEW DRUG APPLICATION**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 29 November 2021.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, Suzhou Junjing Biomedical Technology Co., Ltd. *(蘇州君境生物醫藥科技有限公司), a company was jointly invested by the Company and Wigen Biomedicine Technology (Shanghai) Co., Ltd. (“**Wigen Biomedicine**”) has received the Acceptance Notice (《受理通知書》) issued by the National Medical Products Administration. The investigational new drug application for the Aurora A inhibitor WJ05129 tablets (project code: “**JS112**”) has been accepted. Relevant information is as follows:

ABOUT JS112

Drug name: WJ05129 tablets

Application matter: Clinical Trial of Domestic Production Registration of Pharmaceutical Product
Acceptance No.: CXHL2101685, CXHL2101686

Applicant: Suzhou Junjing Biomedical Technology Co., Ltd.*(蘇州君境生物醫藥科技有限公司)

Review conclusion: It is decided to be accepted upon review according to the requirements of Article 32 of the Administrative Licensing Law of People's Republic of China.

JS112 is an oral small molecule Aurora A inhibitor. As a member of serine/threonine protein kinases in the Aurora kinase family, Aurora A plays an important role in the process of cell mitosis. By inhibiting recombinant protein A, breast cancer susceptibility protein-1 (BRCA1) and BRCA2, Aurora A disrupts DNA damage and reparation. Aurora A inhibitor and RB1 gene deletion or inactivation have a synthetic lethal effect, and can be used to treat malignant tumors with RB1 deletion or inactivation, such as small cell lung cancer and triple negative breast cancer. As of the date of this announcement, no Aurora A inhibitor has been approved for marketing globally. The Company has the world-wide exclusive production rights, licensed production rights and sales rights for JS112 (further details set out in the announcement of the Company dated 16 September 2020).

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development projects and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 29 November 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Jiang Hualiang and Dr. Roy Steven Herbst as independent non-executive Directors.

* *For identification purpose only*